Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/6/2008

- Company Provides R&D Pipeline Update -

IRVINE, Calif., March 6 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today reported financial results for the year ended December 31, 2007. ISTA reported net revenue of $58.9 million for the year ended December 31, 2007, a 78% increase over the full-year 2006 results of $33.0 million. Net revenue in the fourth quarter of 2007 increased 56% over the fourth quarter of 2006.

"2007 was a year of success and challenges. On the commercial front, we more than doubled our Xibrom revenues in 2007 as compared to 2006. Xibrom has significant momentum in the ophthalmic market, and this growth is expected to continue in 2008. Istalol continues to gain share on its branded competitor in a highly genericized therapeutic category," stated Vicente Anido Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals. "On the clinical front, we announced positive results from ISTA's Phase II/III Bepreve study and committed ourselves to accelerating the remainder of its clinical development program, which is now fully enrolled. With the in-licensing of the rights to nasal bepotastine, we also have added another key asset to ISTA's pipeline. We believe nasal bepotastine will be a cornerstone of our future growth, as we explore ISTA's commercial options outside ophthalmology."

Dr. Anido continued, "As Xibrom is our lead product, we completed the clinical development for Xibrom QD and filed the NDA for this once-daily formulation at the end of last year. In reviewing the file, the FDA requested additional data comparing Xibrom QD to the currently marketed Xibrom twice- daily formulation, and ISTA has therefore administratively withdrawn the clinical se
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
2. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
3. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
7. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
10. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
11. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , ... August 26, 2015 , ... ... announces today that a second US laboratory is to open in Manhattan, Kansas ... the continued partnership and long-term growth of research and development through collaboration with ...
(Date:8/26/2015)... 2015  The Diabetes Research Institute (DRI), a ... Miller School of Medicine, announced today that the ... for the first time a novel transplant technique ... approved Phase I/II study builds upon decades of ... important first step toward the development of the ...
(Date:8/26/2015)... , Aug. 26, 2015 China Cord Blood ... China,s leading provider of cord blood collection, ... storage services, today announced that the Company has been ... an entity wholly owned by Mr. Yuen Kam, chairman ... acquired the outstanding shares (the "Shares") of  Excellent China ...
(Date:8/26/2015)... , ... August 26, 2015 , ... The 2015 Epigenomics ... adult stem cell technology start-up company Asymmetrex to share the first report ... of a new biomarker for counting adult tissue stem cells. , With a name ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
... Third Quarter 2008 GAAP Earnings Per Share were $1.09, an Increase from ... Per Share of $0.18, Full Year Revenue Guidance Raised from $14.6 Billion ... $14.9 Billion ... to $4.45 - $4.55, THOUSAND OAKS, Calif., Oct. 22 Amgen (Nasdaq:,AMGN) ...
... the leader in,automated proofreading solutions for the pharmaceutical ... pharmaceutical companies have selected Global,Vision to help them ... from,occurring in their packaging process. The integration of ... quality issues and,costs, along with speeding up product ...
... antagonist now approved in single-use ... ... US, Inc. today,announced that the U.S. Food and Drug Administration ... hydrochloride,injection) Premixed in 5% Dextrose. Discovered and developed by Astellas,Vaprisol, ...
Cached Biology Technology:Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 2Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 3Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 4Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 5Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 6Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 7Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 8Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 9Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 10Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 11Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 12Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 13Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 14Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 15Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 16Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 17Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 18Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 19Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 20Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 21Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 22Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 23Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 24Global Vision Recognized for Helping Pharmaceutical Companies Achieve Complete Artwork and Copy Accuracy in their Packaging Process 2FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 2FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 3FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 4
(Date:8/5/2015)... New York , August 5, 2015 ... market report titled "Facial Recognition Market - Global Industry ... 2022", the global market for facial recognition is forecast ... is driven by increased demand for surveillance systems by ... the rising number of crimes and terrorist activities across ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... a cellular trigger that normally regulates replenishment of ... in mice. Removing the abnormal stimulation causes the ... a possible treatment for the lethal, aggressive brain ... Erica L. Jackson, of the University of California, ...
... published by BioMed Central, the open access publisher, received ... in the top 10 of their 2005 Journal Citation ... Factor exceeding 3.00, open access journals are confirmed as ... Central's flagship title covering biology in the post-genomic era, ...
... scientists working at the epicenter of the AIDS epidemic ... virus (HIV) "exhausts" killer T cells that would otherwise ... simply "turn off" fully functional T cells by flipping ... studies, however, the scientists showed that they could reinvigorate ...
Cached Biology News:Possible birthplace of malignant brain tumors identified 2Impressive new Impact Factors for BioMed Central's open-access journals 2How HIV 'exhausts' killer T cells 2How HIV 'exhausts' killer T cells 3How HIV 'exhausts' killer T cells 4